IFTBF (Infant Bacterial Therapeutics AB) Volatility: 47.86% (As of Jun. 25, 2026)


IFTBF Infant Bacterial Therapeutics AB IFTBF
29 GF Score
Price $6.18
! 1 Warning Sign
View Full Analysis

What is Infant Bacterial Therapeutics AB Volatility?

Infant Bacterial Therapeutics AB IFTBF 29 Volatility is 47.86% as of Jun. 25, 2026. GuruFocus rates IFTBF with a GF Score™ of 29/100. The stock has 1 warning sign investors should review.

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2026-06-25), Infant Bacterial Therapeutics AB's Volatility is 47.86%.


Infant Bacterial Therapeutics AB  (OTCPK:IFTBF) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.


Infant Bacterial Therapeutics AB Volatility Related Terms


IFTBF vs VRTX, REGN, ALNY: Volatility Comparison

For the Biotechnology subindustry, Infant Bacterial Therapeutics AB's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Infant Bacterial Therapeutics AB Volatility vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Infant Bacterial Therapeutics AB's Volatility distribution charts can be found below:

* The bar in red indicates where Infant Bacterial Therapeutics AB's Volatility falls into.


IFTBF
29GF Score
Infant Bacterial Therapeutics AB IFTBF
Volatility is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Infant Bacterial Therapeutics AB  (OTCPK:IFTBF) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * 12
= 1/(n-1) ∑(Ri - R')^2 * 12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Volatility →
What does a Volatility of 47.86% mean?
Infant Bacterial Therapeutics AB (IFTBF) has a Volatility of 47.86% as of Jun. 25, 2026. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Infant Bacterial Therapeutics AB and its competitors.
Is Infant Bacterial Therapeutics AB's Volatility too high?
Infant Bacterial Therapeutics AB's current Volatility is 47.86%. Overall, Infant Bacterial Therapeutics AB has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Infant Bacterial Therapeutics AB's Volatility compare to VRTX and REGN?
Infant Bacterial Therapeutics AB's Volatility of 47.86% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Volatility for a Biotechnology company?
A good Volatility depends on the Biotechnology industry context. However, Volatility should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Volatility mean?
A high Volatility can signal that a stock is expensive relative to its fundamentals. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Infant Bacterial Therapeutics AB and its competitors. Infant Bacterial Therapeutics AB's current Volatility is 47.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Infant Bacterial Therapeutics AB stock overvalued right now?
Infant Bacterial Therapeutics AB (IFTBF) has a current Volatility of 47.86%. The current Volatility is 47.86%. Infant Bacterial Therapeutics AB's overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Volatility calculated?
Volatility is calculated from a company's financial statements. For Infant Bacterial Therapeutics AB (IFTBF), the current Volatility is 47.86% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Infant Bacterial Therapeutics AB Business Description

Other Exchanges IBT B:Sweden9IB:Germany
Address Katarina Bangata 70, Stockholm, SWE, 116 42
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance, Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118, and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.
29GF Score

Get the complete analysis for IFTBF

Volatility is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.18
Price